When TIGIT interacts with its primary ligand CD155 on DC or cancer cell membranes or with CD112 expressed by tumor cells and APC in the tumor microenvironment, it induces a decrease in the proinflammatory cytokine secretion, proliferation, and killing function of immune cells [53,54]. The gene discussed is PVR; the disease is neoplasm.